Workflow
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
NeurocrineNeurocrine(US:NBIX) Prnewswireยท2025-05-05 12:30

Core Insights - The survey conducted by The Harris Poll highlights the significant negative impact of tardive dyskinesia (TD) on patients' daily lives, emphasizing the need for routine screening, earlier diagnosis, and treatment [1][2][3] Functional Impact - 80% of patients with TD wished they had been screened earlier, and 86% wanted their healthcare providers to discuss treatment options sooner [1][4] - 43% of all patients and 40% of those with mild/moderate TD required assistance with daily activities due to their symptoms [4] - 41% of all patients and 40% of those with mild/moderate TD were unable to perform their job functions because of their symptoms [4] Psychological Impact - 86% of patients felt judged or stared at due to their movements, and 82% agreed that their uncontrolled movements brought unwanted attention to their mental health condition [4] - 80% of patients felt that others made incorrect assumptions about them because of their movements [4] Social Impact - 56% of all patients and 55% of those with mild/moderate TD avoided going out in public [4] - 44% of all patients and 46% of those with mild/moderate TD avoided leaving home [4] - 40% of all patients and 43% of those with mild/moderate TD experienced limited professional interactions [4] - 40% of all patients and 34% of those with mild/moderate TD missed work or school due to their symptoms [4] Awareness and Education - The survey results indicate a need for continued education about TD, especially among individuals taking antipsychotic medications [3][5] - Only 47% of patients were informed by their providers about the potential contribution of their mental health medications to their symptoms prior to diagnosis [10] - 83% of people with TD wished they had been encouraged to discuss their uncontrolled movements with healthcare providers earlier [10] Company Commitment - Neurocrine Biosciences is dedicated to improving awareness and education regarding TD, providing resources for patients and healthcare professionals [8][12]